BioXcel Therapeutics (BTAI) Reports Q2 Loss of $1.06/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 7:00 AM EDTSERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) planned for Q1 2021
Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patients
Initiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) to include patients with castrate-resistant prostate cancer (CRPC)
Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceeds
Company... More
